Glucotrack Reports First Quarter 2026 Financial Results and Recent Corporate Highlights
Glucotrack submitted an Investigational Device Exemption (IDE) application to the FDA to initiate a U.S. clinical study for its fully implantable continuous blood glucose monitor (CBGM). The company targets launching the U.S. clinical trial in the second half of 2026, supported by peer-reviewed data showing a 6.8% MARD and long-term sensor stability in preclinical models.
Key figures
- Revenue
- 0
- Mard
- 6.8%
- Net loss
- 4334000
- Ga expense
- 2071000
- Rd expense
- 2132000
- Cash and equivalents
- 3929000
- Promissory note balance
- 1600000
AI analysis
Red flags2 · Pro
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.